Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Microbix Biosystems Inc T.MBX

Alternate Symbol(s):  MBXBF

Healthcare Biotechnology
Microbix Biosystems Inc. develops and commercializes biological and technological solutions for human health and wellbeing. It enables the commercialization of diagnostic assays by making a range of critical ingredients and devices for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products (QAPs) that support clinical lab proficiency testing, enable assay development and validation, or help ensure the quality of clinical diagnostic workflows. Its segments include development, manufacturing and sales of products relating to the medical diagnostics industry, namely antigens as test ingredients, quality assessment products to help ensure the accuracy of test workflows and viral transport medium to enable collection of patient test samples and, and development and commercialization of novel and proprietary products or technologies, such as Kinlytic. Its Kinlytic urokinase is a biologic thrombolytic drug used to treat blood clots.


TSX:MBX - Post by User

Microbix Biosystems Inc > digital newsletter
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(96)
•••
Comment by wizzdumbon Apr 07, 2022 3:07pm
113 Views
Post# 34585385

RE:RE:digital newsletter

RE:RE:digital newsletter

Fourth building, that's new news that's never been mentioned before. 

Late spring or early summer they will be cranking out the VTM as governments and private companies are stocking up for the inevitable fall/winter surge at a rate of 50-100K per WEEK. That's seven times current capacity. They are on or ahead of schedule which is amazing job with all the supply chain and labor shortages everywhere. 

Second quarter results May 12. 

The most exciting time in MBX history is slowly unfolding, don't get left behind. 

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities